AR and neoplasm: Preclinical studies have shown that enzalutamide promotes tumor cell apoptosis in LAR and non-LAR TNBC subtype cell lines, thus suggesting that enzalutamide may be available even in TNBC cell lines with weakly positive AR expression48.